We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

51 hedge funds and large institutions have $27.9M invested in Theriva Biologics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more capital invested

Capital invested by funds: $20.6M → $27.9M (+$7.27M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

4% less funds holding

Funds holding: 53 → 51 (-2)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
51
Holders Change
-2
Holders Change %
-3.77%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
7
Reduced
7
Closed
9
Calls
$9.75M
Puts
–
Net Calls
+$9.75M
Net Calls Change
+$3.84M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$121K
2
BlackRock
BlackRock
New York
+$116K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$69.4K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$63.6K
5
PPA
Parametric Portfolio Associates
Washington
+$63.6K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.5M
2
William Blair & Company
William Blair & Company
Illinois
-$906K
3
Goldman Sachs
Goldman Sachs
New York
-$639K
4
UOC
UBS O'Connor
Illinois
-$424K
5
PP
Paloma Partners
Connecticut
-$207K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPIA
51
Steward Partners Investment Advisory
New York
$4K – – –
TWA
52
TCI Wealth Advisors
Arizona
$3K – – –
TRCT
53
Tower Research Capital (TRC)
New York
$1K -$17.3K -3 Closed
AFNAS
54
American Financial Network Advisory Services
California
$1K – – –
Citigroup
55
Citigroup
New York
$1K – – –
KF
56
Krilogy Financial
Missouri
$1K – – –
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$20 – – –
William Blair & Company
58
William Blair & Company
Illinois
– -$906K -183 Closed
Goldman Sachs
59
Goldman Sachs
New York
– -$639K -129 Closed
UOC
60
UBS O'Connor
Illinois
– -$424K -86 Closed
PP
61
Paloma Partners
Connecticut
– -$207K -42 Closed
LP
62
LMR Partners
United Kingdom
– -$194K -39 Closed
Susquehanna International Group
63
Susquehanna International Group
Pennsylvania
– -$107K -22 Closed
SM
64
Sabby Management
Florida
– -$95K -19 Closed
Barclays
65
Barclays
United Kingdom
– -$62K -13 Closed
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$2K – –
1 2
3

TOVX Hedge Fund Activity: Q3 2017 in Review

51 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2017, worth a combined $27.9M — up 35% from $20.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TOVX and 8 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $121K. The largest seller was Alyeska Investment Group, cutting an estimated $1.5M.

  • 51 institutional investors held Theriva Biologics (TOVX) as of Q3 2017, down from 53 in Q2 2017.
  • Funds reported $27.9M of Theriva Biologics stock for Q3 2017, up 35% quarter-over-quarter.
  • 8 funds opened new Theriva Biologics positions in Q3 2017 and 9 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q3 2017 was Vanguard Group, an estimated $121K added.
  • The largest Theriva Biologics seller in Q3 2017 was Alyeska Investment Group, an estimated $1.5M sold.

Based on aggregated 13F filings for Q3 2017.